Pain Management Nursing
Volume 8, Issue 3 , Pages 113-121 , September 2007

Mechanisms of Opioid-Induced Tolerance and Hyperalgesia

  • Anna DuPen, MN, ARNP

      Affiliations

    • Pain and Palliative Care Research Department, Swedish Medical Center, Seattle, Washington
    • Corresponding Author InformationAddress correspondence to Anna DuPen, MN, ARNP, Pain and Palliative Care Research Department, Swedish Medical Center, 500 17th Ave, Providence Professional Building Suite 405, Seattle, WA 98122-5711.
    • ,
  • Danny Shen, PhD

      Affiliations

    • Departments of Pharmacy and Pharmaceutics, University of Washington School of Pharmacy, Seattle, Washington.
    • ,
  • Mary Ersek, PhD, RN

      Affiliations

    • Center for Nursing Excellence, Swedish Medical Center, Seattle, Washington

References 

  1. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology. 2006;104:570–587
  2. Arden JR, Segredo V, Wang Z, Lameh J, Sadee W. Phosphorylation and agonist-specific intracellular trafficking of an epitope-tagged mu-opioid receptor expressed in HEK 293 cells. Journal of Neurochemistry. 1995;65:1636–1645
  3. Benitez del Rosario MA, Feria M, Salinas-Martin A, Martinez-Castillo LP, Martin-Ortega JJ. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain. Cancer. 2004;101:2866–2873
  4. Bergen AW, Kokoszka J, Peterson R, Long JC, Virkkunen M, Linnoila M, et al. Mu opioid receptor gene variants: lack of association with alcohol dependence. Molecular Psychiatry. 1997;2:490–494
  5. Bernstein ZP, Yucht S, Battista E, Lema M, Spaulding MB. Proglumide as a morphine adjunct in cancer pain management. Journal of Pain & Symptom Management. 1998;15:314–320
  6. Bohn LM, Lefkowitz RJ, Caron MG. Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice. Journal of Neuroscience. 2002;22:10494–10500
  7. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science. 1999;286:2495–2498
  8. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proceeding of the National Academies of Science of the United States of America. 1998;95:9608–9613
  9. Celerier E, Rivat C, Jun Y, Laulin JP, Larcher A, Reynier P, et al. Long-lasting hyperalgesia induced by fentanyl in rats: Preventive effect of ketamine. Anesthesiology. 2000;92:465–472
  10. Chavkin C, Goldstein A. Reduction in opiate receptor reserve in morphine tolerant guinea pig ilea. Life Sciences. 1982;31:1687–1690
  11. Chavkin C, Goldstein A. Opioid receptor reserve in normal and morphine-tolerant guinea pig ileum myenteric plexus. Proceeding of the National Academies of Science of the United States of America. 1984;81:7253–7257
  12. Chindalore VL, Craven RA, Yu KP, Butera PG, Burns LH, Friedmann N. Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex. Journal of Pain. 2005;6:392–399
  13. Clark JL, Kalan GE. Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patient. Journal of Pain & Symptom Management. 1995;10:310–314
  14. Collin E, Poulain P, Gauvain-Piquard A, Petit G, Pichard-Leandri E. Is disease progression the major factor in morphine “tolerance” in cancer pain treatment?. Pain. 1993;55:319–326
  15. Compton MA. Cold-pressor pain tolerance in opiate and cocaine abusers: correlates of drug type and use status. Journal of Pain & Symptom Management. 1994;9:462–473
  16. Compton P, Charuvastra VC, Ling W. Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent. Drug & Alcohol Dependence. 2001;63:139–146
  17. Crain SM, Shen KF. Antagonists of excitatory opioid receptor functions enhance morphine’s analgesic potency and attenuate opioid tolerance/dependence liability. Pain. 2000;84:121–131
  18. Davis AM, Inturrisi CE. d-Methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia. Journal of Pharmacol Exp Ther. 1999;289:1048–1053
  19. De Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. Journal of Pain Symptom & Management. 1995;10:378–384
  20. Dourish CT, Hawley D, Iversen SD. Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by the cholecystokinin antagonist L-364,718. European Journal of Pharmacology. 1988;147:469–472
  21. Doverty M, White JM, Somogyi AA, Bochner F, Ali R, Ling W. Hyperalgesic responses in methadone maintenance patients. Pain. 2001;90:91–96
  22. Drake R, Longworth J, Collins JJ. Opioid rotation in children with cancer. Journal of Palliative Medicine. 2004;7:419–422
  23. Duttaroy A, Yoburn BC. The effect of intrinsic efficacy on opioid tolerance. Anesthesiology. 1995;82:1226–1236
  24. Eilers H, Philip LA, Bickler PE, McKay WR, Schumacher MA. The reversal of fentanyl-induced tolerance by administration of “small-dose” ketamine. Anesthesia & Analgesia. 2001;93:213–214
  25. Elliott K, Hynansky A, Inturrisi CE. Dextromethorphan attenuates and reverses analgesic tolerance to morphine. Pain. 1994;59:361–368
  26. Estfan B, LeGrand SB, Walsh D, Lagman RL, Davis MP. Opioid rotation in cancer patients: pros and cons. Oncology (Williston Park). 2005;19:511–516
  27. Ferguson SS, Zhang J, Barak LS, Caron MG. Role of beta-arrestins in the intracellular trafficking of G-protein–coupled receptors. Advances in Pharmacology. 1998;42:420–424
  28. Finn AK, Whistler JL. Endocytosis of the mu opioid receptor reduces tolerance and a cellular hallmark of opiate withdrawal. Neuron. 2001;32:829–839
  29. Foley K. Changing concepts of tolerance to opioids: what the cancer patient has taught us. In:  Chapman CR,  Foley KM editor. Current and emerging issues in cancer pain: research and practice. New York: Raven Press; 1993;p. 331–350
  30. Galer BS, Lee D, Ma T, Schlagheck T. MorphiDex (morphine sulfate/dextromethorphan hydrobromide combination) in the treatment of chronic pain: three multicenter randomized, double-blind, controlled clinical trials fail to demonstrate enhanced opioid analgesia or reduction in tolerance. Pain. 2005;115:284–295B., N.
  31. Gardell LR, King T, Ossipov MH, Rice KC, Lai J, Vanderah TW, et al. Opioid receptor–mediated hyperalgesia and antinociceptive tolerance induced by sustained opiate delivery. Neuroscience Letters. 2006;396:44–49
  32. Gardell LR, Wang R, Burgess SE, Ossipov MH, Vanderah TW, Malan TP, et al. Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. Journal of Neuroscience. 2002;22:6747–6755
  33. Gorman AL, Elliott KJ, Inturrisi CE. The d- and l-isomers of methadone bind to the noncompetitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neuroscience Letters. 1997;223:5–8
  34. Haley JE, Sullivan AF, Dickenson AH. Evidence for spinal N-methyl-D-aspartate receptor involvement in prolonged chemical nociception in the rat. Brain Research. 1990;518:218–226
  35. Hirota T, Ieiri I, Takane H, Sano H, Kawamoto K, Aono H, et al. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metabolism & Disposition. 2003;31:677–680
  36. Ho KY, Gan TJ, Habib AS. Gabapentin and postoperative pain—a systematic review of randomized controlled trials. Pain. 2006;126:91–101
  37. Indelicato RA, Portenoy RK. Opioid rotation in the management of refractory cancer pain. Journal of Clinical Oncology. 2002;20:348–352
  38. Ivarsson M, Neil A. Differences in efficacies between morphine and methadone demonstrated in the guinea pig ileum: a possible explanation for previous observations on incomplete opioid cross-tolerance. Pharmacology & Toxicology. 1989;65:368–371
  39. King T, Ossipov MH, Vanderah TW, Porreca F, Lai J. Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid antinociceptive tolerance?. Neurosignals. 2005;14:194–205
  40. Kloke M, Rapp M, Bosse B, Kloke O. Toxicity and/or insufficient analgesia by opioid therapy: risk factors and the impact of changing the opioid (A retrospective analysis of 273 patients observed at a single center). Support Care in Cancer. 2000;8:479–486
  41. Lauretti GR, Lima IC, Reis MP, Prado WA, Pereira NL. Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. Anesthesiology. 1999;90:1528–1533
  42. Li T, Zhu ZH, Liu X, Hu X, Zhao J, Sham PC, et al. Association analysis of polymorphisms in the DRD4 gene and heroin abuse in Chinese subjects. American Journal of Medical Genetics. 2000;96:616–621
  43. Lotsch J, Skarke C, Grosch S, Darimont J, Schmidt H, Geisslinger G. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics. 2002;12:3–9
  44. Lotsch J, Zimmermann M, Darimont J, Marx C, Dudziak R, Skarke C, et al. Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity?. Anesthesiology. 2002;97:814–819
  45. Luttrell LM, Lefkowitz RJ. The role of beta-arrestins in the termination and transduction of G-protein–coupled receptor signals. Journal of Cell Science. 2002;115:455–465
  46. Lynch ME. A review of the use of methadone for the treatment of chronic noncancer pain. Pain Research & Management. 2005;10:133–144
  47. Mansour A, Fox CA, Akil H, Watson SJ. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends in Neuroscience. 1995;18:22–29
  48. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ. Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain. Journal of Neuroscience. 1987;7:2445–2464
  49. Mao J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain. 2002;100:213–217
  50. Mao J. Opioid-induced abnormal pain sensitivity. Current Pain & Headache Reports. 2006;10:67–70
  51. Mao J, Price DD, Mayer DJ. Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C. Journal of Neuroscience. 1994;14:2301–2312
  52. Mao J, Price DD, Mayer DJ. Experimental mononeuropathy reduces the antinociceptive effects of morphine: implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain. Pain. 1995;61:353–364
  53. Mao J, Sung B, Ji RR, Lim G. Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity. Journal of Neuroscience. 2002;22:8312–8323
  54. McCleane GJ. Cholecystokinin antagonists a new way to improve the analgesia from old analgesics?. Current Pharmaceutical Design. 2004;10:303–314
  55. McCleane GJ. The cholecystokinin antagonist proglumide enhances the analgesic efficacy of morphine in humans with chronic benign pain. Anesthesia & Analgesia. 1998;87:1117–1120
  56. McCleane GJ. The cholecystokinin antagonist proglumide enhances the analgesic effect of dihydrocodeine. Clinical Journal of Pain. 2003;19:200–201
  57. McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. Journal of Pain. 2003;4:231–256
  58. Mercadante S. Ketamine in cancer pain: an update. Palliative Medicine. 1996;10:225–230
  59. Mercadante S. Opioid rotation for cancer pain: rationale and clinical aspects. Cancer. 1999;86:1856–1866
  60. Morley JS. Opioid rotation: does it have a role?. Palliative Medicine. 1998;12:464–466
  61. Moulin DE, Ling GS, Pasternak GW. Unidirectional analgesic cross-tolerance between morphine and levorphanol in the rat. Pain. 1988;33:233–239
  62. Noble F, Cox BM. Differential desensitization of mu- and delta- opioid receptors in selected neural pathways following chronic morphine treatment. British Journal of Pharmacology. 1996;117:161–169
  63. Ossipov MH, Lai J, King T, Vanderah TW, Porreca F. Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure. Biopolymers. 2005;80:319–324
  64. Pasternak GW. Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends in Pharmacological Sciences. 2001;22:67–70
  65. Perry SJ, Lefkowitz RJ. Arresting developments in heptahelical receptor signaling and regulation. Trends in Cell Biology. 2002;12:130–138
  66. Price DD, von der Gruen A, Miller J, Rafii A, Price C. Potentiation of systemic morphine analgesia in humans by proglumide, a cholecystokinin antagonist. Anesthesia & Analgesia. 1985;64:801–806
  67. Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database of Systematic Reviews. 2004;3:CD004847
  68. Quirion R. Pain, nociception and spinal opioid receptors. Progress in Neuro-psychopharmacology & Biological Psychiatry. 1984;8:571–579
  69. Quirion R, Zajac JM, Morgat JL, Roques BP. Autoradiographic distribution of mu and delta opiate receptors in rat brain using highly selective ligands. Life Sciences. 1983;33(Suppl 1):227–230
  70. Raehal KM, Bohn LM. Mu opioid receptor regulation and opiate responsiveness. AAPS Journal. 2005;7:E587–E591
  71. Ross JR, Riley J, Quigley C, Welsh KI. Clinical pharmacology and pharmacotherapy of opioid switching in cancer patients. Oncologist. 2006;11:765–773
  72. Ross JR, Rutter D, Welsh K, Joel SP, Goller K, Wells AU, et al. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics Journal. 2005;5:324–336
  73. Saeki S, Yaksh TL. Suppression of nociceptive responses by spinal mu opioid agonists: effects of stimulus intensity and agonist efficacy. Anesthesia & Analgesia. 1993;77:265–274
  74. Sander T, Gscheidel N, Wendel B, Smolka M, Rommelspacher H, Schmidt LG, et al. Human mu-opioid receptor variation and alcohol dependence. AlcoholismClinical & Experimental Research. 1998;22:2108–2110
  75. Shen KF, Crain SM. Cholera toxin-A subunit blocks opioid excitatory effects on sensory neuron action potentials indicating mediation by Gs-linked opioid receptors. Brain Research. 1990;525:225–231
  76. Sim-Selley LJ, Selley DE, Vogt LJ, Childers SR, Martin TJ. Chronic heroin self-administration desensitizes mu opioid receptor–activated G-proteins in specific regions of rat brain. Journal of Neuroscience. 2000;20:4555–4562
  77. Sim LJ, Selley DE, Dworkin SI, Childers SR. Effects of chronic morphine administration on mu opioid receptor–stimulated [35S]GTPgammaS autoradiography in rat brain. Journal of Neuroscience. 1996;16:2684–2692
  78. Sjogren P, Thunedborg LP, Christrup L, Hansen SH, Franks J. Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administration? Six case histories. Acta Anaesthesiologica Scandinavica. 1998;42:1070–1075
  79. Sosnowski M, Yaksh TL. Differential cross-tolerance between intrathecal morphine and sufentanil in the rat. Anesthesiology. 1990;73:1141–1147
  80. Tang J, Chou J, Iadarola M, Yang HY, Costa E. Proglumide prevents and curtails acute tolerance to morphine in rats. Neuropharmacology. 1984;23:715–718
  81. Terman GW, Jin W, Cheong YP, Lowe J, Caron MG, Lefkowitz RJ, et al. G-Protein receptor kinase 3 (GRK3) influences opioid analgesic tolerance but not opioid withdrawal. British Journal of Pharmacology. 2004;141:55–64
  82. Terner JM, Barrett AC, Lomas LM, Negus SS, Picker MJ. Influence of low doses of naltrexone on morphine antinociception and morphine tolerance in male and female rats of four strains. Pain. 2006;122:90–101
  83. Thomsen AB, Becker N, Eriksen J. Opioid rotation in chronic nonmalignant pain patients (A retrospective study). Acta Anaesthesiologica Scandinavica. 1999;43:918–923
  84. Town T, Abdullah L, Crawford F, Schinka J, Ordorica PI, Francis E, et al. Association of a functional mu-opioid receptor allele (+118A) with alcohol dependency. American Journal of Medical Genetics. 1999;88:458–461
  85. Van Bockstaele EJ, Colago EE, Cheng P, Moriwaki A, Uhl GR, Pickel VM. Ultrastructural evidence for prominent distribution of the mu-opioid receptor at extrasynaptic sites on noradrenergic dendrites in the rat nucleus locus coeruleus. Journal of Neuroscience. 1996;16:5037–5048
  86. Vanderah TW, Gardell LR, Burgess SE, Ibrahim M, Dogrul A, Zhong CM, et al. Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. Journal of Neuroscience. 2000;20:7074–7079
  87. Vanderah TW, Suenaga NM, Ossipov MH, Malan TP, Lai J, Porreca F. Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. Journal of Neuroscience. 2001;21:279–286
  88. Vigano A, Fan D, Bruera E. Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators. Pain. 1996;67:115–119
  89. Wang HY, Friedman E, Olmstead MC, Burns LH. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor–G protein coupling and Gbetagamma signaling. Neuroscience. 2005;135:247–261
  90. Watkins LR, Kinscheck IB, Mayer DJ. Potentiation of opiate analgesia and apparent reversal of morphine tolerance by proglumide. Science. 1984;224:395–396
  91. White PF. The changing role of nonopioid analgesic techniques in the management of postoperative pain. Anesthesia & Analgesia. 2005;101(5 Suppl):S5–S22
  92. Xu XJ, Wiesenfeld-Hallin Z, Hughes J, Horwell DC, Hokfelt T. CI988, a selective antagonist of cholecystokininB receptors, prevents morphine tolerance in the rat. British Journal of Pharmacology. 1992;105:591–596
  93. Yabaluri N, Medzihradsky F. Down-regulation of mu-opioid receptor by full but not partial agonists is independent of G protein coupling. Molecular Pharmacology. 1997;52:896–902
  94. Yoburn BC, Gomes BA, Rajashekara V, Patel C, Patel M. Role of G(i)alpha2-protein in opioid tolerance and mu-opioid receptor downregulation in vivo. Synapse. 2003;47:109–116

PII: S1524-9042(07)00076-8

doi: 10.1016/j.pmn.2007.02.004

Pain Management Nursing
Volume 8, Issue 3 , Pages 113-121 , September 2007

Article Tools

* Image Usage & Resolution